Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2108)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (106)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (211)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4653)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
    Meeting Abstract

    Hurvitz, S. A.; Kalinsky, K.; Tripathy, D.; Sledge, G.; Gradishar, W. J.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
    Meeting Abstract

    Kuboki, Y.; Yaeger, R.; Fakih, M. G.; Strickler, J. H.; Masuishi, T.; Kim, E. J.; Bestvina, C. M.; Langer, C. J.; Krauss, J. C.; Puri, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Meeting Abstract

    Kopetz, S.; Murphy, D. A.; Pu, J.; Yaeger, R.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Alkuzweny, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Meeting Abstract

    Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Meeting Abstract

    Vernieri, C.; Zattarin, E.; Mariani, L.; Menichetti, A.; Leporati, R.; Ligorio, F.; Fuca, G.; Lobefaro, R.; Griguolo, G.; Sirico, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
    Meeting Abstract

    Schmid, P.; Cortés, J.; Marmé, F.; Rugo, H. S.; Tolaney, S. M.; Oliveira, M.; Loirat, D.; Jhaveri, K.; Yoon, O. K.; Motwani, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
    Meeting Abstract

    Friedman, C.; Swanton, C.; Spigel, D.; Bose, R.; Burris, H.; Yu, W.; Wang, Y.; Malato, J.; Price, R.; Darbonne, W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Kasper, S.; Segal, N. H.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; Amirouchene Angelozzi, N.; Amirouchene da Silva, A. P.; St-Pierre, A.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Prospective study to evaluate pathological complete response after neoadjuvant therapy in breast cancer: Are we ready to avoid surgery?
    Meeting Abstract

    Rossi, E. M. C.; De Scalzi, A. M.; Girardi, A.; Pesapane, F.; Invento, A.; dominelli, V.; De Lorenzi, F.; Sacchini, V.; Veronesi, P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Marra, A.; Gazzo, A.; Gupta, A.; Selenica, P.; Da Silva, E. M.; Pareja, F.; Pei, X.; Zhu, Y.; Razavi, P.; Safonov, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save